Everything below concerns glucagon receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-17. Numbers and descriptions here follow the published literature rather than marketing material.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
β-carotene can be extracted from fungus Blakeslea trispora, marine algae Dunaliella salina or genetically modified yeast Saccharomyces cerevisiae, starting with xylose as a substrate. Chemical synthesis uses either a method developed by BASF or a Grignard reaction utilized by Hoffman-La Roche. The world market for synthetic retinol is primarily for animal feed, leaving approximately 13% for a combination of food, prescription medication and dietary supplement use. Industrial methods for the production of retinol rely on chemical synthesis. The first industrialized synthesis of retinol was achieved by the company Hoffmann-La Roche in 1947. In the following decades, eight other companies developed their own processes. β-ionone, synthesized from acetone, is the essential starting point for all industrial syntheses. Each process involves elongating the unsaturated carbon chain. Pure retinol is extremely sensitive to oxidization and is prepared and transported at low temperatures and oxygen-free atmospheres. When prepared as a dietary supplement or food additive, retinol is stabilized as the ester derivatives retinyl acetate or retinyl palmitate. Prior to 1999, three companies, Roche, BASF and Rhone-Poulenc controlled 96% of global vitamin A sales. In 2001, the European Commission imposed total fines of 855.22 million euros on these and five other companies for their participation in eight distinct market-sharing and price-fixing cartels that dated back to 1989. Roche sold its vitamin division to DSM in 2003. DSM and BASF have the major share of industrial production.
== Nazi Germany (1933–1945) == Soon after Adolf Hitler was appointed as chancellor in 1933, the German Reichstag (parliament) passed the Enabling Act (German: Ermächtigungsgesetz), officially titled "Law for Removing the Distress of People and Reich" (German: Gesetz zur Behebung der Not von Volk und Reich), which effectively gave the chancellor the power of a dictator. This event marked the end of the Weimar Republic and the beginning of Nazi Germany. Hitler thereupon destroyed all democratic systems and consolidated all power to himself. After the death of president Paul von Hindenburg in 1934, Hitler merged the offices of chancellor and president in his own person and called himself Führer und Reichskanzler. Political parties: NSDAP
=== Late stage === During the final stage, known as the late-stage or severe stage, there is complete dependence on caregivers. Language is reduced to simple phrases or even single words, eventually leading to complete loss of speech. Despite the loss of verbal language abilities, people can often understand and return emotional signals. Although aggressiveness can still be present, extreme apathy and exhaustion are much more common symptoms. People with Alzheimer's disease will ultimately not be able to perform even the simplest tasks independently; muscle mass and mobility deteriorate to the point where they are bedridden and unable to feed themselves. The cause of death is usually an external factor, such as infection of pressure ulcers or pneumonia, not the disease itself. In some cases, there is a paradoxical lucidity immediately before death, where there is an unexpected recovery of mental clarity.
Alan H. B. Wu is an American clinical chemist, toxicologist, professor, and author. He is known for his work in laboratory medicine, particularly in clinical chemistry, cardiac biomarkers, pharmacogenomics, and clinical toxicology. He is a professor of Laboratory Medicine at the University of California, San Francisco (UCSF), and Chief of Clinical Chemistry and Toxicology and Co-Core Lab Director at the Zuckerberg San Francisco General Hospital.
== Boxing scandals == List of deaths due to injuries sustained in boxing In 1967, then-undefeated World Champion Muhammad Ali was stripped of his title, and denied a boxing license for the next 3 years over his refusal to be drafted into the U.S. army. In 1983, boxer Luis Resto was caught tampering with his gloves by removing padding and hardening his hand wraps with plaster. In 2001, International Boxing Federation founder Robert W. "Bobby" Lee Sr. was convicted of money laundering and tax evasion, following a three-year long investigation of racketeering and bribery at the organization. Tampered handwraps controversy of 2009 resulting in the suspension of Antonio Margarito Suspension of boxing judges at the 2016 Summer Olympics - see Boxing at the 2016 Summer Olympics#Judging
Sources: en.wikipedia.org
== See also == Crystal structure prediction Dynamical system Memetics Metastability Ostwald's rule of stages Protein folding#Misfolded proteins Prion Protein folding#Energy landscape of protein folding Proteinopathy#Seeded induction Schild's Ladder Self-replicating machine Self-replication Strangelet#Potential propagation
==== Metal base-pairs ==== In metal base-pairing, the Watson-Crick hydrogen bonds are replaced by the interaction between a metal ion with nucleosides acting as ligands. The possible geometries of the metal that would allow for duplex formation with two bidentate nucleosides around a central metal atom are tetrahedral, dodecahedral, and square planar. Metal-complexing with DNA can occur by the formation of non-canonical base pairs from natural nucleobases with participation by metal ions and also by the exchanging the hydrogen atoms that are part of the Watson-Crick base pairing by metal ions. Introduction of metal ions into a DNA duplex has shown to have potential magnetic or conducting properties, as well as increased stability. Metal complexing has been shown to occur between natural nucleobases. A well-documented example is the formation of T-Hg-T, which involves two deprotonated thymine nucleobases that are brought together by Hg2+ and forms a connected metal-base pair. This motif does not accommodate stacked Hg2+ in a duplex due to an intrastrand hairpin formation process that is favored over duplex formation. Two thymines across from each other do not form a Watson-Crick base pair in a duplex; this is an example where a Watson-Crick basepair mismatch is stabilized by the formation of the metal-base pair. Another example of a metal complexing to natural nucleobases is the formation of A-Zn-T and G-Zn-C at high pH; Co2+ and Ni2+ also form these complexes. These are Watson-Crick base pairs where the divalent cation in coordinated to the nucleobases.
== Research == There is evidence that paroxetine may be effective in the treatment of compulsive gambling and hot flashes. Benefits of paroxetine prescription for diabetic neuropathy or chronic tension headache are uncertain. Although the evidence is conflicting, paroxetine may be effective for the treatment of dysthymia, a chronic disorder involving depressive symptoms for most days of the year. There is evidence to support that paroxetine selectively binds to and inhibits G protein-coupled receptor kinase 2 (GRK2) in mice with heart failure. Since GRK2 regulates the activity of the beta adrenergic receptor, which becomes desensitized in cases of heart failure, paroxetine (or a paroxetine derivative) could be used as a heart failure treatment in the future. Paroxetine has been identified as a potential disease-modifying osteoarthritis drug.
=== Digestibility-corrected AAS, DIAAS === DIAAS considers the profile of the essential amino acids that are actually absorbed. This value is calculated by estimating the amount of each EAA absorbed in the "test protein" by comparing how much of each EAA went into the mouth and how much was pumped out of the end of the small intestines. This was then turned into a profile Ai by dividing the amounts in milligrams of each EAA with the grams of the test protein eaten. From then on, the calculation is similar:
Sources: en.wikipedia.org
Relaxin-3 is a neuropeptide that was discovered in 2001, and which is highly conserved in species ranging from flies, fish, rodents and humans. Relaxin-3 is a member and ancestral gene of the relaxin family of peptides, which includes the namesake hormone relaxin (designated 'H2 relaxin' in humans) which mediates peripheral actions during pregnancy and which was found to relax the pelvic ligament in guinea pigs almost a century ago. The cognate receptor for relaxin-3 is the G-protein coupled receptor RXFP3 (relaxin family peptide 3 receptor), however relaxin-3 is pharmacologically able to also cross react with RXFP1 and RXFP3 (although the physiological relevance of such interactions, if they exist endogenously, are currently unknown).
Hot dogs are a traditional element of American food culture, having obtained significant cultural and patriotic status from their association with public events and sports since the 1920s. Cultural traditions include the Nathan's Hot Dog Eating Contest and the Oscar Mayer Wienermobile. In the US, the term hot dog refers to both the sausage by itself and the combination of sausage and bun. Many nicknames applying to either have emerged over the years, including frankfurter, frank, wiener, weenie, coney, and red hot. Annually, Americans consume 20 billion hot dogs.
The new product exhibited chemical properties of an alkali metal (such as coprecipitating with caesium salts), which led Perey to believe that it was element 87, caused by the alpha decay of actinium-227. Perey then attempted to determine the proportion of beta decay to alpha decay in actinium-227. Her first test put the alpha branching at 0.6%, a figure that she later revised to 1%.
Myostatin (also known as growth differentiation factor 8, abbreviated GDF8) is a protein that in humans is encoded by the MSTN gene. Myostatin is a myokine that is produced and released by myocytes and acts on muscle cells to inhibit muscle growth. Myostatin is a secreted growth differentiation factor that is a member of the TGF beta protein family. Myostatin is assembled and produced in skeletal muscle before it is released into the blood stream. Most of the data regarding the effects of myostatin comes from studies performed on mice. Animals either lacking myostatin or treated with substances that block the activity of myostatin have significantly more muscle mass. Furthermore, individuals who have mutations in both copies of the myostatin gene (popularly called the "Hercules gene") have significantly more muscle mass and are stronger than normal. There is hope that studies into myostatin may have therapeutic application in treating muscle wasting diseases such as muscular dystrophy.
== Nervous control == The mechanical states of catch connective tissue are under nervous control and thus we can regard this tissue as one of neurally controlled mechano-effectors such as muscles. It is found in the sea-urchin spine joints that the stiffness of catch connective tissue changes in the coordinated manner with the muscle contractions. One of the characteristic cells found in catch connective tissue is juxtaligamental cells containing secretory granules. These cells are supposed to contain proteins controlling stiffness of extracellular materials. When stained with the antibody specific to echinoderm nerves sea-cucumber body wall is supplied with immunoreactive fine fibers running among the collagen fibrils. Pharmacological experiments suggested the presence of two types of cholinergic systems, one is the nicotinic one involved in the dermal stiffening and the other is the muscarinic one involved in softening. Cholinergic nerves seem to control the secretory activities of juxtaligamental cells. The presence of the cholinergic system was supported by the neuropeptide stichopin that inhibits the action of stiffening cholinergic systems. Stichopin is one of four new peptides in the dermis of sea cucumbers. Other ones are the neuropeptide NGIWYamide that stiffens the dermis and two holokinins that soften the dermis. The nerves containing these neuropeptides possibly control the secretory activities of juxtaligamental cells.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.